Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2017-09, Vol.28, p.v447-v447 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | v447 |
|---|---|
| container_issue | |
| container_start_page | v447 |
| container_title | Annals of oncology |
| container_volume | 28 |
| creator | Rozeman, E.A. Deken, M.A. Gadiot, J. Geukes Foppen, M.H. Pronk, L. Thienen, J.V. Haanen, J.B. Blank, C.U. |
| description | |
| doi_str_mv | 10.1093/annonc/mdx377.044 |
| format | Article |
| fullrecord | <record><control><sourceid>elsevier_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_annonc_mdx377_044</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0923753420385203</els_id><sourcerecordid>S0923753420385203</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1374-c6a0b2db19816c16f0c48626b0a859cb943054e0e455c39189d524155817cef63</originalsourceid><addsrcrecordid>eNp9kL9OwzAQhy0EEqXwAGwe2yGtndhOLKZStVDRigoKa-Q4DjHKP9kOpTwXD0jasrAwnXS633d3HwDXGI0w4sFYVFVdyXGZfgZhOEKEnIAepox7ESL4FPQQ9wMvpAE5BxfWviOEGPd5D3yvc2EV9OGza9MdnNZlI4yu3uBalYmpC_3VliKBW-1yuKicMqV2TlVubPPaOG_fgGkrCriarB9gI1y-FTuoq1wn2um6gk3R2r-wwXq2GnYj-2ndoSzMhUnqw1aXK3j7NJm_MoRg2TpxYAwWq45wawTcGC2K4SU4y0Rh1dVv7YOX-WwzvfeWj3eL6WTpSRyExJNMoMRPE8wjzCRmGZIkYj5LkIgolwknAaJEIUUolQHHEU-pTzClEQ6lyljQB_jIlaa21qgsbowuhdnFGMV77fFRe3zUHnfau8zNMaO6wz60MrGV3ZdSpdoo6eK01v-kfwBSm48z</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Rozeman, E.A. ; Deken, M.A. ; Gadiot, J. ; Geukes Foppen, M.H. ; Pronk, L. ; Thienen, J.V. ; Haanen, J.B. ; Blank, C.U.</creator><creatorcontrib>Rozeman, E.A. ; Deken, M.A. ; Gadiot, J. ; Geukes Foppen, M.H. ; Pronk, L. ; Thienen, J.V. ; Haanen, J.B. ; Blank, C.U.</creatorcontrib><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdx377.044</identifier><language>eng</language><publisher>Elsevier Ltd</publisher><ispartof>Annals of oncology, 2017-09, Vol.28, p.v447-v447</ispartof><rights>2017 European Society for Medical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Rozeman, E.A.</creatorcontrib><creatorcontrib>Deken, M.A.</creatorcontrib><creatorcontrib>Gadiot, J.</creatorcontrib><creatorcontrib>Geukes Foppen, M.H.</creatorcontrib><creatorcontrib>Pronk, L.</creatorcontrib><creatorcontrib>Thienen, J.V.</creatorcontrib><creatorcontrib>Haanen, J.B.</creatorcontrib><creatorcontrib>Blank, C.U.</creatorcontrib><title>Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)</title><title>Annals of oncology</title><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNp9kL9OwzAQhy0EEqXwAGwe2yGtndhOLKZStVDRigoKa-Q4DjHKP9kOpTwXD0jasrAwnXS633d3HwDXGI0w4sFYVFVdyXGZfgZhOEKEnIAepox7ESL4FPQQ9wMvpAE5BxfWviOEGPd5D3yvc2EV9OGza9MdnNZlI4yu3uBalYmpC_3VliKBW-1yuKicMqV2TlVubPPaOG_fgGkrCriarB9gI1y-FTuoq1wn2um6gk3R2r-wwXq2GnYj-2ndoSzMhUnqw1aXK3j7NJm_MoRg2TpxYAwWq45wawTcGC2K4SU4y0Rh1dVv7YOX-WwzvfeWj3eL6WTpSRyExJNMoMRPE8wjzCRmGZIkYj5LkIgolwknAaJEIUUolQHHEU-pTzClEQ6lyljQB_jIlaa21qgsbowuhdnFGMV77fFRe3zUHnfau8zNMaO6wz60MrGV3ZdSpdoo6eK01v-kfwBSm48z</recordid><startdate>201709</startdate><enddate>201709</enddate><creator>Rozeman, E.A.</creator><creator>Deken, M.A.</creator><creator>Gadiot, J.</creator><creator>Geukes Foppen, M.H.</creator><creator>Pronk, L.</creator><creator>Thienen, J.V.</creator><creator>Haanen, J.B.</creator><creator>Blank, C.U.</creator><general>Elsevier Ltd</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201709</creationdate><title>Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)</title><author>Rozeman, E.A. ; Deken, M.A. ; Gadiot, J. ; Geukes Foppen, M.H. ; Pronk, L. ; Thienen, J.V. ; Haanen, J.B. ; Blank, C.U.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1374-c6a0b2db19816c16f0c48626b0a859cb943054e0e455c39189d524155817cef63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rozeman, E.A.</creatorcontrib><creatorcontrib>Deken, M.A.</creatorcontrib><creatorcontrib>Gadiot, J.</creatorcontrib><creatorcontrib>Geukes Foppen, M.H.</creatorcontrib><creatorcontrib>Pronk, L.</creatorcontrib><creatorcontrib>Thienen, J.V.</creatorcontrib><creatorcontrib>Haanen, J.B.</creatorcontrib><creatorcontrib>Blank, C.U.</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rozeman, E.A.</au><au>Deken, M.A.</au><au>Gadiot, J.</au><au>Geukes Foppen, M.H.</au><au>Pronk, L.</au><au>Thienen, J.V.</au><au>Haanen, J.B.</au><au>Blank, C.U.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial)</atitle><jtitle>Annals of oncology</jtitle><date>2017-09</date><risdate>2017</risdate><volume>28</volume><spage>v447</spage><epage>v447</epage><pages>v447-v447</pages><issn>0923-7534</issn><eissn>1569-8041</eissn><pub>Elsevier Ltd</pub><doi>10.1093/annonc/mdx377.044</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2017-09, Vol.28, p.v447-v447 |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_annonc_mdx377_044 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Phase 2 Study Comparing Pembrolizumab with Intermittent/short-term dual MAPK pathway inhibition plus Pembrolizumab(PEM) in patients harboring the BRAFV600 mutation (IMPemBra Trial) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T06%3A17%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-elsevier_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%202%20Study%20Comparing%20Pembrolizumab%20with%20Intermittent/short-term%20dual%20MAPK%20pathway%20inhibition%20plus%20Pembrolizumab(PEM)%20in%20patients%20harboring%20the%20BRAFV600%20mutation%20(IMPemBra%20Trial)&rft.jtitle=Annals%20of%20oncology&rft.au=Rozeman,%20E.A.&rft.date=2017-09&rft.volume=28&rft.spage=v447&rft.epage=v447&rft.pages=v447-v447&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdx377.044&rft_dat=%3Celsevier_cross%3ES0923753420385203%3C/elsevier_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_els_id=S0923753420385203&rfr_iscdi=true |